Browse Studies — Arctuva

Phase 1

A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)

This is a Phase Ib in adult patients with relapsed or refractory EBV-positive DLBCL using daily oral dosing of VK-2019 in three dose escalation cohorts: 600 mg…

Diffuse Large B Cell Lymphoma RefractoryDiffuse Large B Cell Lymphoma RelapsedEpstein-Barr Virus (EBV) Infection

Estimated

~$10 – $7,500

Pierluigi PorcuNCT06789159

Phase 3

A Phase 3 Randomized Controlled Trial of Rondecabtagene Autoleucel , an Autologous, Dual-targeting CD19/CD20 CAR T-Cell Product Candidate, Vs. Investigator's Choice of CD19 CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-Cell Lymphoma in the Second-line Setting

This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell…

Large B-cell LymphomaLymphoma, B-CellRelapsed Non-Hodgkin Lymphoma+6 more

Estimated

~$10 – $8,750

Lyell Immunopharma, Inc.NCT07188558

Phase 1

A Pilot Trial of Bridging Radiation Therapy With Oral Vancomycin for Patients With B-cell Lymphomas Undergoing CAR-T Therapy

This clinical trial assesses whether it is feasible to use radiation therapy with vancomycin prior to CAR T-cell therapy for patients with large B-cell lymphom…

Large B Cell LymphomaNon Hodgkin Lymphoma (NHL)Diffuse Large B Cell Lymphoma (DLBCL)+2 more

Estimated

~$10 – $6,250

Abramson Cancer Center at Penn MedicineNCT07478848